2nd Quarter - Report
W STRATEGIES, LLC for ASTRAZENECA PHARMACEUTICALS LP
Firm
Income
$50,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Education about the 340(b) drug discount program including the CMS 340(b) CMP Rule. H.R.2430/S.934: FDA Reauthorization Act of 2017. H.R.1628: American Health Care Act. Better Care Reconciliation Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Medicare/Medicaid MMM
H.R.1834: Cancer Care Payment Reform Act of 2017. H.R.849/H.J.Res 51: IPAB Repeal Act and Joint Resolution related to IPAB Repeal.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.